The urgent need for new antibacterial agents

Richard Wise; Martin Blaser; Otto Carrs; Gail Cassell; Neil Fishman; Robert Guidos; Stuart Levy; John Powers; Ragnar Norrby; Glenn Tillotson; Rick Davies; Steven Projan; Mike Dawson; Dominique Monnet; Marcus Keogh-Brown; Kieran Hand; Sarah Garner; David Findlay; Chantal Morel; Richard Wise; Richard Bax; Frances Burke; Ian Chopra; Lloyd Czaplewski; Roger Finch; David Livermore; Laura J.V. Piddock; Tony White

doi:10.1093/jac/dkr261

The urgent need for new antibacterial agents

Richard Wise^*, Martin Blaser, Otto Carrs, Gail Cassell, Neil Fishman, Robert Guidos, Stuart Levy, John Powers, Ragnar Norrby, Glenn Tillotson, Rick Davies, Steven Projan, Mike Dawson, Dominique Monnet, Marcus Keogh-Brown, Kieran Hand, Sarah Garner, David Findlay, Chantal Morel, Richard Wise^*Richard Bax, Frances Burke, Ian Chopra, Lloyd Czaplewski, Roger Finch, David Livermore, Laura J.V. Piddock, Tony White

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

102 Citations (Scopus)

Original language	English
Article number	dkr261
Pages (from-to)	1939-1940
Number of pages	2
Journal	Journal of Antimicrobial Chemotherapy
Volume	66
Issue number	9
DOIs	https://doi.org/10.1093/jac/dkr261
Publication status	Published - Sept 2011

Bibliographical note

Funding Information:
D. L. has received conference, speaking and research support from numerous pharmaceutical companies. He holds shares in AstraZeneca, Merck, Pfizer, Dechra, and GlaxoSmithKline, and, as executor, manages further holdings in GlaxoSmithKline and Eco Animal Health. He is an employee of the UK HPA and is a UK taxpayer. R. B. is currently a senior partner at Transcrip partners LLP and works with several large and small pharmaceutical companies in the area of antibiotic development. He is also a non-executive director of Helperby Therapeutics Ltd. R. F. has provided consultative advice to Destiny Pharma, Glaxo-SmithKline, Menarini Recherche and Novartis. F. B. is an employee of Eli Lilly and Company Ltd. I. C. is a member of the Scientific Advisory Board of Destiny Pharma Ltd and has recently received research funding from Cubist, Destiny, Galapagos, Leo, Pfizer, Novartis and Novacta. T. W. is an independent consultant, a retired employee and shareholder of GlaxoSmithKline, and in the past 5 years has received financial remuneration for consultancy or presentations from GSK and Chiron/Novartis. The remaining members of the Working Party have none to declare.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkr261

Cite this

Wise, R., Blaser, M., Carrs, O., Cassell, G., Fishman, N., Guidos, R., Levy, S., Powers, J., Norrby, R., Tillotson, G., Davies, R., Projan, S., Dawson, M., Monnet, D., Keogh-Brown, M., Hand, K., Garner, S., Findlay, D., Morel, C., ... White, T. (2011). The urgent need for new antibacterial agents. Journal of Antimicrobial Chemotherapy, 66(9), 1939-1940. Article dkr261. https://doi.org/10.1093/jac/dkr261

@article{bc207b9cb47244cbb9f6e728b129b586,

title = "The urgent need for new antibacterial agents",

author = "Richard Wise and Martin Blaser and Otto Carrs and Gail Cassell and Neil Fishman and Robert Guidos and Stuart Levy and John Powers and Ragnar Norrby and Glenn Tillotson and Rick Davies and Steven Projan and Mike Dawson and Dominique Monnet and Marcus Keogh-Brown and Kieran Hand and Sarah Garner and David Findlay and Chantal Morel and Richard Wise and Richard Bax and Frances Burke and Ian Chopra and Lloyd Czaplewski and Roger Finch and David Livermore and Piddock, {Laura J.V.} and Tony White",

note = "Funding Information: D. L. has received conference, speaking and research support from numerous pharmaceutical companies. He holds shares in AstraZeneca, Merck, Pfizer, Dechra, and GlaxoSmithKline, and, as executor, manages further holdings in GlaxoSmithKline and Eco Animal Health. He is an employee of the UK HPA and is a UK taxpayer. R. B. is currently a senior partner at Transcrip partners LLP and works with several large and small pharmaceutical companies in the area of antibiotic development. He is also a non-executive director of Helperby Therapeutics Ltd. R. F. has provided consultative advice to Destiny Pharma, Glaxo-SmithKline, Menarini Recherche and Novartis. F. B. is an employee of Eli Lilly and Company Ltd. I. C. is a member of the Scientific Advisory Board of Destiny Pharma Ltd and has recently received research funding from Cubist, Destiny, Galapagos, Leo, Pfizer, Novartis and Novacta. T. W. is an independent consultant, a retired employee and shareholder of GlaxoSmithKline, and in the past 5 years has received financial remuneration for consultancy or presentations from GSK and Chiron/Novartis. The remaining members of the Working Party have none to declare.",

year = "2011",

month = sep,

doi = "10.1093/jac/dkr261",

language = "English",

volume = "66",

pages = "1939--1940",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "9",

}

Wise, R, Blaser, M, Carrs, O, Cassell, G, Fishman, N, Guidos, R, Levy, S, Powers, J, Norrby, R, Tillotson, G, Davies, R, Projan, S, Dawson, M, Monnet, D, Keogh-Brown, M, Hand, K, Garner, S, Findlay, D, Morel, C, Wise, R, Bax, R, Burke, F, Chopra, I, Czaplewski, L, Finch, R, Livermore, D, Piddock, LJV & White, T 2011, 'The urgent need for new antibacterial agents', Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, dkr261, pp. 1939-1940. https://doi.org/10.1093/jac/dkr261

TY - JOUR

T1 - The urgent need for new antibacterial agents

AU - Wise, Richard

AU - Blaser, Martin

AU - Carrs, Otto

AU - Cassell, Gail

AU - Fishman, Neil

AU - Guidos, Robert

AU - Levy, Stuart

AU - Powers, John

AU - Norrby, Ragnar

AU - Tillotson, Glenn

AU - Davies, Rick

AU - Projan, Steven

AU - Dawson, Mike

AU - Monnet, Dominique

AU - Keogh-Brown, Marcus

AU - Hand, Kieran

AU - Garner, Sarah

AU - Findlay, David

AU - Morel, Chantal

AU - Wise, Richard

AU - Bax, Richard

AU - Burke, Frances

AU - Chopra, Ian

AU - Czaplewski, Lloyd

AU - Finch, Roger

AU - Livermore, David

AU - Piddock, Laura J.V.

AU - White, Tony

N1 - Funding Information: D. L. has received conference, speaking and research support from numerous pharmaceutical companies. He holds shares in AstraZeneca, Merck, Pfizer, Dechra, and GlaxoSmithKline, and, as executor, manages further holdings in GlaxoSmithKline and Eco Animal Health. He is an employee of the UK HPA and is a UK taxpayer. R. B. is currently a senior partner at Transcrip partners LLP and works with several large and small pharmaceutical companies in the area of antibiotic development. He is also a non-executive director of Helperby Therapeutics Ltd. R. F. has provided consultative advice to Destiny Pharma, Glaxo-SmithKline, Menarini Recherche and Novartis. F. B. is an employee of Eli Lilly and Company Ltd. I. C. is a member of the Scientific Advisory Board of Destiny Pharma Ltd and has recently received research funding from Cubist, Destiny, Galapagos, Leo, Pfizer, Novartis and Novacta. T. W. is an independent consultant, a retired employee and shareholder of GlaxoSmithKline, and in the past 5 years has received financial remuneration for consultancy or presentations from GSK and Chiron/Novartis. The remaining members of the Working Party have none to declare.

PY - 2011/9

Y1 - 2011/9

UR - http://www.scopus.com/inward/record.url?scp=80051686188&partnerID=8YFLogxK

U2 - 10.1093/jac/dkr261

DO - 10.1093/jac/dkr261

M3 - Article

C2 - 21700627

AN - SCOPUS:80051686188

SN - 0305-7453

VL - 66

SP - 1939

EP - 1940

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 9

M1 - dkr261

ER -

The urgent need for new antibacterial agents

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this